Drug Profile
Rifaximin - Alfasigma
Alternative Names: Dermodis; EIR formulation of rifaximin - Salix Pharmaceuticals; Flonorm; L-105; Lumenax; Normix; RedActive®; Rifacol; Rifaxidin®; Rifaximin soluble solid dispersion tablet; Rifaximin SSD; Rifaximin-a 550mg; rifaximin-alpha; Rifxima; SLX-G1043; SLX-G1063; SLX-L1042; SLX-L1044; Spiraxin; Targaxan 550; Tixtar; Xifaxan; Xifaxan 550mg; XIFAXAN550; Xifaxanta; ZaxineLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Alfa Wassermann SpA
- Developer Alfa Wassermann SpA; Alfasigma; ASKA Pharmaceutical; Bausch Health Companies; Lupin; Norgine; Salix Pharmaceuticals; University of Washington; Yokohama City University
- Class Anti-infectives; Anti-inflammatories; Antianaemics; Antibacterials; Antidiarrhoeals; Hepatoprotectants; Irritable bowel syndrome therapies; Rifamycins; Skin disorder therapies; Small molecules
- Mechanism of Action DNA-directed RNA polymerase inhibitors; Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diverticulitis; Hepatic encephalopathy; Hyperammonaemia; Intestinal infections; Irritable bowel syndrome; Skin and soft tissue infections; Traveller's diarrhoea
- Phase III Crohn's disease; Liver disorders
- Phase II Intestinal obstruction; Rosacea; Sickle cell anaemia
- Phase Unknown COVID 2019 infections
- No development reported Unspecified
- Discontinued Bacterial vaginosis; Clostridium difficile infections; Pouchitis; Shigella infections
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in New Zealand (PO, Capsule)
- 04 Sep 2023 Bausch Health Americas completes a phase II trial in Sickle cell anaemia (In adults, In the elderly) in USA, Canada, Kenya (PO) (NCT05098028)
- 17 May 2023 US district court upholds final judgment for rifaximin that prevents FDA approval of Norwich's ANDA until 2029